Pharma
Revvity launched Signals AI on June 22, 2026, a native agentic framework embedded within its Signals One platform that allows scientists to query, interpret and act on research and development (R&D) data using natural language. The Massachusetts-based health science company, which reported $2.9 billion in revenue for 2025, said the launch marks a shift in how its scientific software handles knowledge.
“The addition of the Signals AI capabilities within Revvity’s Signals One platform reflects a fundamental shift in how scientists work with R&D knowledge,” said Kevin Willoe, president of Revvity Signals Software.
According to the company, Signals AI introduces an intelligence layer into Signals One that lets researchers engage directly with connected R&D data across experiments, instruments, applications and systems. The challenge for scientific organisations is no longer collecting data but converting it into decisions and action, the company said.
